PURPOSE: Tumor necrosis factor (TNF)-alpha is a mediator of neuronal cell death and survival in ischemia-reperfusion injury. This study was conducted to further elucidate the role of TNF-alpha and its receptor in an in vivo model of retinal ischemia-reperfusion injury by investigating its effects on retinal histopathology and function. METHODS: Retinal ischemia-reperfusion injury was performed on p55 and p75 knockout (KO) mice and Sprague-Dawley rats using the high intraocular pressure METHOD: The temporal expression of TNF-alpha was ascertained with immunohistochemical staining. Separate rats received intravitreal recombinant TNF-alpha or neutralizing antibody before or after ischemia. TUNEL labeling was performed to assess for cell death, and electroretinography was performed to assess function. RESULTS: TNF-alpha expression peaked at 12 to 24 hours after ischemia-reperfusion injury. TUNEL staining was diminished after intravitreal TNF-alpha antibody. Both transgenic KOs demonstrated significantly less functional impairment. Rats receiving recombinant TNF-alpha 48 hours after ischemia showed exaggerated functional impairment. Animals treated with TNF-alpha antibody before ischemia displayed significant functional improvement. CONCLUSIONS: TNF-alpha plays a largely deleterious role in ischemia-reperfusion injury in an in vivo model of retinal injury. Direct neutralization of this cytokine partially preserves retinal function. The diverse characteristics of TNF-alpha are attributed in part to the timing of its expression after injury. TNF-alpha receptor expression and function, along with combination treatments targeting death receptor-mediated apoptosis, should be further explored to develop neuroprotective therapeutic strategies for acute retinal ischemic disorders.
PURPOSE:Tumor necrosis factor (TNF)-alpha is a mediator of neuronal cell death and survival in ischemia-reperfusion injury. This study was conducted to further elucidate the role of TNF-alpha and its receptor in an in vivo model of retinal ischemia-reperfusion injury by investigating its effects on retinal histopathology and function. METHODS:Retinal ischemia-reperfusion injury was performed on p55 and p75 knockout (KO) mice and Sprague-Dawley rats using the high intraocular pressure METHOD: The temporal expression of TNF-alpha was ascertained with immunohistochemical staining. Separate rats received intravitreal recombinant TNF-alpha or neutralizing antibody before or after ischemia. TUNEL labeling was performed to assess for cell death, and electroretinography was performed to assess function. RESULTS:TNF-alpha expression peaked at 12 to 24 hours after ischemia-reperfusion injury. TUNEL staining was diminished after intravitreal TNF-alpha antibody. Both transgenic KOs demonstrated significantly less functional impairment. Rats receiving recombinant TNF-alpha 48 hours after ischemia showed exaggerated functional impairment. Animals treated with TNF-alpha antibody before ischemia displayed significant functional improvement. CONCLUSIONS:TNF-alpha plays a largely deleterious role in ischemia-reperfusion injury in an in vivo model of retinal injury. Direct neutralization of this cytokine partially preserves retinal function. The diverse characteristics of TNF-alpha are attributed in part to the timing of its expression after injury. TNF-alpha receptor expression and function, along with combination treatments targeting death receptor-mediated apoptosis, should be further explored to develop neuroprotective therapeutic strategies for acute retinal ischemic disorders.
Authors: Joel David; Aleksandr Melamud; Leo Kesner; Steven Roth; Pearl S Rosenbaum; Frank C Barone; Sussana Popp; Getaw Worku Hassen; Alfred Stracher; Daniel M Rosenbaum Journal: Neuroreport Date: 2011-09-14 Impact factor: 1.837
Authors: Irina G Obrosova; Yury Maksimchyk; Pal Pacher; Elisabet Agardh; Maj-Lis Smith; Azza B El-Remessy; Carl-David Agardh Journal: Int J Mol Med Date: 2010-07 Impact factor: 4.101
Authors: Frédéric Lebrun-Julien; Mathieu J Bertrand; Olivier De Backer; David Stellwagen; Carlos R Morales; Adriana Di Polo; Philip A Barker Journal: Proc Natl Acad Sci U S A Date: 2010-02-03 Impact factor: 11.205
Authors: Craig E Crosson; Santhosh K Mani; Shahid Husain; Oday Alsarraf; Donald R Menick Journal: Invest Ophthalmol Vis Sci Date: 2010-02-17 Impact factor: 4.799
Authors: Jose-Andres C Portillo; Jin-Sang Yu; Samuel Hansen; Timothy S Kern; M Cecilia Subauste; Carlos S Subauste Journal: FASEB J Date: 2021-03 Impact factor: 5.191